CO-FOUNDER/CHAIRMAN/CEO , TARSUS PHARMACEUTICALS
WHY:Chief executive of Irvinebased development-stage drugmaker with a focus on eye care. Since its 2016 founding, Tarsus has completed fundraising efforts through an IPO and global partnerships.
IN THE NEWS:The company, which employs 240 people, is developing the TP-03, a novel, topical therapeutic to treat Demodex blepharitis, an ocular disease that occurs when Demodex mites—the most common ectoparasite found on humans—infest the eyelid.
NOTABLE:Azamian co-founded and led two other therapeutics companies—Vibrato Medical, focused on wearable treatments for peripheral arterial diseases, and Metavention, focused on interventional treatments for metabolic diseases—and led both through multiple financings.
